Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients

References

• Boillee S., Vande Velde C., Cleveland D. W. ALS: a disease of motor neurons and their non‐neuronal neighbors. Neuron 2006; 52: 39–59
   PubMed Web of Science ®Google Scholar
• Graves M. C., Fiala M., Dinglasan L. A., Liu N. Q., Sayre J., Chiappelli F., et al. Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T‐cells. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 213–9
   PubMed Web of Science ®Google Scholar
• McGeer P. L., McGeer E. G. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 2002; 26: 459–70
   PubMed Web of Science ®Google Scholar
• Bruijn L. I., Cudkowicz M. Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies. Expert Rev Neurother 2006; 6: 417–28
   PubMedGoogle Scholar
• McGeer E. G., McGeer P. L. Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. BioDrugs 2005; 19: 31–7
   PubMed Web of Science ®Google Scholar
• Avidan H., Kipnis J., Butovsky O., Caspi R. R., Schwartz M. Vaccination with autoantigen protects against aggregated beta‐amyloid and glutamate toxicity by controlling microglia: effect of CD4+CD25+ T‐cells. Eur J Immunol 2004; 34: 3434–45
   PubMed Web of Science ®Google Scholar
• Angelov D. N., Waibel S., Guntinas‐Lichius O., Lenzen M., Neiss W. F., Tomov T. L., et al. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2003; 100: 4790–5
   PubMed Web of Science ®Google Scholar
• Schori H., Kipnis J., Yoles E., WoldeMussie E., Ruiz G., Wheeler L. A., et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci U S A 2001; 98: 3398–403
   PubMed Web of Science ®Google Scholar
• Kipnis J., Yoles E., Porat Z., Cohen A., Mor F., Sela M., et al. T‐cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci U S A 2000; 97: 7446–51
   PubMed Web of Science ®Google Scholar
• Aharoni R., Arnon R., Eilam R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J Neurosci 2005; 25: 8217–28
   PubMed Web of Science ®Google Scholar
• Teitelbaum D., Brenner T., Abramsky O., Aharoni R., Sela M., Arnon R. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler 2003; 9: 592–9
   PubMed Web of Science ®Google Scholar
• Farina C., Weber M. S., Meinl E., Wekerle H., Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 2005; 4: 567–75
   PubMed Web of Science ®Google Scholar
• Arnon R., Sela M. Immunomodulation by the copolymer glatiramer acetate. J Mol Recognit 2003; 16: 412–21
   PubMed Web of Science ®Google Scholar
• Gordon P. H., Doorish C., Montes J., Mosley R. L., Diamond B., Macarthur R. B., et al. Randomized controlled phase II trial of glatiramer acetate in ALS. Neurology 2006; 66: 1117–9
   PubMed Web of Science ®Google Scholar
• Zhang K. Accessibility control and machinery of immunoglobulin class switch recombination. J Leukoc Biol 2003; 73: 323–32
   PubMed Web of Science ®Google Scholar
• Basile E., Gibbs E., Aziz T., Oger J. During three years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4. J Neuroimmunol 2006; 177: 161–6
   PubMed Web of Science ®Google Scholar
• Brenner T., Arnon R., Sela M., Abramsky O., Meiner Z., Riven‐Kreitman R., et al. Humoral and cellular immune responses to copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001; 115: 152–60
   PubMed Web of Science ®Google Scholar
• Dhib‐Jalbut S. Glatiramer acetate (Copaxone) therapy for multiple sclerosis. Pharmacol Ther 2003; 98: 245–55
   PubMed Web of Science ®Google Scholar
• Farina C., Vargas V., Heydari N., Kumpfel T., Meinl E., Hohlfeld R. Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients. J Neuroimmunol 2002; 123: 188–92
   PubMed Web of Science ®Google Scholar
• Adams D., Kuntzer T., Burger D., Chofflon M., Magistris M. R., Regli F., et al. Predictive value of anti‐GM1 ganglioside antibodies in neuromuscular diseases: a study of 180 sera. J Neuroimmunol 1991; 32: 223–30
   PubMed Web of Science ®Google Scholar
• van Schaik I. N., Bossuyt P. M., Brand A., Vermeulen M. Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta‐analysis. Neurology 1995; 45: 1570–7
   PubMed Web of Science ®Google Scholar
• Haggiag S., Steiner‐Birmanns B., Wirguin I., Sicsic C., Brenner T., Steiner I. Seroconversion of anti‐GM1 antibodies in patients with amyotrophic lateral sclerosis. Neurology 2004; 63: 755–6
   PubMed Web of Science ®Google Scholar
• Smith R. G., Siklos L., Alexianu M. E., Engelhardt J. I., Mosier D. R., Colom L., et al. Autoimmunity and ALS. Neurology. 1996; 47: S40–5
   Google Scholar
• Niebroj‐Dobosz I., Dziewulska D., Janik P. Auto‐antibodies against proteins of spinal cord cells in cerebrospinal fluid of patients with amyotrophic lateral sclerosis (ALS). Folia Neuropathol 2006; 44: 191–6
   PubMed Web of Science ®Google Scholar
• Lisak R. P., Zwiman B., Norman M. Antimyelin antibodies in neurologic diseases. Immunofluorescent demonstration. Arch Neurol 1975; 32: 163–7
   PubMedGoogle Scholar
• Abrams G. M., Latov N., Hays A. P., Sherman W., Zimmerman E. A. Immunocytochemical studies of human peripheral nerve with serum from patients with polyneuropathy and paraproteinemia. Neurology 1982; 32: 821–6
   PubMed Web of Science ®Google Scholar
• Teitelbaum D., Aharoni R., Sela M., Arnon R. Cross‐reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1. Proc Natl Acad Sci U S A 1991; 88: 9528–32
   PubMed Web of Science ®Google Scholar
• Uchitel O. D., Appel S. H., Crawford F., Sczcupak L. Immunoglobulins from amyotrophic lateral sclerosis patients enhance spontaneous transmitter release from motor‐nerve terminals. Proc Natl Acad Sci U S A 1988; 85: 7371–4
   PubMed Web of Science ®Google Scholar
• Kloppenburg M., Dijkmans B. A., Verweij C. L., Breedveld F. C. Inflammatory and immunological parameters of disease activity in rheumatoid arthritis patients treated with minocycline. Immunopharmacology 1996; 31: 163–9
   PubMedGoogle Scholar
• Traynor B. J., Bruijn L., Conwit R., Beal F., O'Neill G., Fagan S. C., et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 2006; 67: 20–7
   PubMed Web of Science ®Google Scholar
• Cudkowicz M. E., Shefner J. M., Schoenfeld D. A., Zhang H., Andreasson K. I., Rothstein J. D., et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006; 60: 22–31
   PubMed Web of Science ®Google Scholar
• Miller A., Shapiro S., Gershtein R., Kinarty A., Rawashdeh H., Honigman S., et al. Treatment of multiple sclerosis with copolymer‐1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune‐deviation. J Neuroimmunol 1998; 92: 113–21
   PubMed Web of Science ®Google Scholar